Cover Image
市場調查報告書

全球眼科用藥市場預測:2017年∼2027年

Global Ophthalmic Drugs Market Forecast 2017-2027: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs

出版商 Visiongain Ltd 商品編碼 239210
出版日期 內容資訊 英文 306 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球眼科用藥市場預測:2017年∼2027年 Global Ophthalmic Drugs Market Forecast 2017-2027: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs
出版日期: 2017年06月14日 內容資訊: 英文 306 Pages
簡介

全球眼科用藥市場,預計從2016年的230億美元,2021年擴大到281億美元。預計市場2017年∼2027年以5.6%的年複合成長率成長。

本報告提供全球眼科用藥市場相關調查分析,市場概要,各市場區隔的市場分析與預測,各地區、各國市場分析與預測,主要企業等相關的系統性資訊。

第1章 報告概要

第2章 所謂眼科用藥

  • 醫藥品產業:概要
  • 人的眼睛:結構纖細且功能性複雜的內臟器官
  • 眼的疾病相關全球負擔
  • 眼科用藥:市場區隔
  • 青光眼:失明主要的原因
  • 老年性黃斑部病變 (AMD)
  • 糖尿病視網膜病變 (DR)
  • 眼的過敏、過敏性結膜炎
  • 眼的發炎性疾病
  • 眼感染疾病
  • 乾眼症症候群
  • 臨床試驗的階段
  • 眼科用藥:市場定義

第3章 全球眼科用藥市場

  • 市場概要
  • 市場分類
  • 市場成果
  • 市場預測
  • 市場佔有率的變化:各部門

第4章 視網膜疾病治療藥市場:市場分析與預測

  • 主要產品
  • 市場趨勢與發展
  • 市場預測
  • 主要的治療藥
  • Eylea (aflibercept) - Regeneron/Bayer/參天製藥
  • Lucentis (ranibizumab) - Roche/Novartis
  • Avastin (bevacizumab) - Roche
  • Visudyne (verteporfin) - Valeant/Novartis
  • Jetrea (ocriplasmin) - ThromboGenics/ Novartis
  • 其他

第5章 過敏性、發炎性、感染性治療藥市場:市場分析與預測

  • 主要產品
  • 市場趨勢與發展
  • 市場預測
  • 主要的治療藥
  • Patanol And Pataday (olopatadine) - Alcon (Novartis)
  • Vigamox (moxifloxacin) - Alcon (Novartis)
  • TobraDex (tobramycin/dexamethasone) - Alcon (Novartis)
  • Cravit (levofloxacin) - 參天製藥
  • Acular (ketorolac) - Allergan (Actavis)
  • AzaSite (azithromycin) - Akorn
  • 其他

第6章 青光眼治療藥市場:市場分析與預測

  • 市場概要
  • 市場趨勢與發展
  • Simbrinza:不用最初的β- 阻斷劑的混合藥
  • 市場預測
  • 主要的治療藥
  • Lumigan And Ganfort (bimatoprost) - Allergan (Actavis)
  • Xalatan And Xalacom (latanoprost) - Pfizer
  • Travatan/Travatan Z and DuoTrav (travoprost)
  • Alphagan/Alphagan P and Combigan (brimonidine)
  • Trusopt And Cosopt/Cosopt PF (dorzolamide)
  • Azopt (brinzolamide) - Novartis
  • Tapros (tafluprost) - 參天製藥
  • Zioptan (tafluprost) - Akorn
  • 其他

第7章 乾眼症治療藥市場:市場分析與預測

  • 市場概要
  • 市場趨勢與發展
  • 市場預測
  • 主要的治療藥
  • Restasis (ciclosporin) - Allergan (Actavis)
  • Refresh Brand Products - Allergan (Actavis)
  • Hyalein (hyaluronic acid) - 參天製藥
  • Diquas (diaquafosol) - 參天製藥
  • 其他

第8章 眼科用藥市場主要國家

  • 各地區
  • 主要國家市場:預測
  • 地區的眼科用藥市場:分析與預測
  • 美國
  • EU5個國家
  • 日本
  • 中國
  • 巴西
  • 俄羅斯
  • 印度
  • 其他

第9章 眼科用藥市場主要企業

  • 眼科治療藥:不斷變化的市場形勢
  • 眼科治療藥市場上主要企業
  • Novartis (Alcon)
  • Regeneron
  • Allergan (Actavis)
  • Roche
  • Valeant
  • 參天製藥
  • Bayer
  • Pfizer
  • 千壽製藥

第10章 眼科用藥:研究開發平台

第11章 眼科用藥市場定性分析

  • 帶來影響的市場要素
  • SWOT分析
  • 波特的五力分析

第12章 結論

第13章 詞彙表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0202

The global ophthalmic drugs market is expected to grow at a CAGR of 4.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.6% from 2017-2027. The market is estimated at $23bn in 2016 and $28.1bn in 2021. In 2016, the retinal disorder drugs submarket held 40% of the share in this market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 306-page report you will receive 125 tables and 113 figures - all unavailable elsewhere.

The 306-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

Global Ophthalmic Drugs market forecasts from 2017-2027

This report also breaks down the revenue forecasts to 2027 for the global ophthalmic drugs market by the leading submarkets:

  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs

This report includes revenue forecasts to 2027 for the following ophthalmic drugs:

  • Eylea
  • Lucentis
  • Avastin
  • Visudyne
  • Jetrea
  • Pataday
  • Vigamox
  • Patanol
  • TobraDex
  • Cravit
  • AzaSite
  • Acular
  • Lumigan and Ganfort
  • Xalatan/Xalacom
  • Travatan/Travatan Z and DuoTrav
  • Alphagan/Alphagan P and Combigan
  • Azopt
  • Trusopt
  • Zioptan
  • Cosopt
  • Tapros/Taflotan
  • Restasis
  • Refresh
  • Hyalein
  • Diquas

This report provides individual revenue forecasts to 2027 for these national markets:

  • The US
  • Japan
  • EU5: Germany, France, the UK, Spain, Italy
  • Russia
  • China
  • India
  • Brazil
  • Rest of the World

Our study provides a SWOT analysis and discusses Porter's Five Forces analysis that influence the global ophthalmic drugs market

Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:

  • Novartis
  • Regeneron
  • Allergan
  • Roche
  • Valeant
  • Santen
  • Bayer
  • Pfizer
  • Senju

Visiongain's study is intended for anyone requiring commercial analyses for the global ophthalmic drugs market. You find data, trends and predictions.

Buy our report today Global Ophthalmic Drugs Market Forecast 2017-2027: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Ophthalmic Drugs: Market Overview
  • 1.2. Global Ophthalmic Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who Is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Reports
  • 1.10. About Visiongain

2. An Introduction to Ophthalmic Drugs

  • 2.1. The Pharmaceutical Industry: A Brief Introduction
    • 2.1.1. Ophthalmic Treatments - An Industry Overview
  • 2.2. The Human Eyes - Structurally Delicate and Functionally Intricate Organs
  • 2.3. The Global Burden of Eye Disease
  • 2.4. Ophthalmic Drugs: Market Segmentation
  • 2.5. Glaucoma: A Major Cause of Vision Loss
    • 2.5.1. A Classification of Glaucoma
    • 2.5.2. Risk Factors for Glaucoma
    • 2.5.3. Diagnosis of Glaucoma
    • 2.5.4. Drug Treatment of Glaucoma
    • 2.5.5. Laser Treatment and Surgery for Glaucoma
  • 2.6. Age-Related Macular Degeneration (AMD)
    • 2.6.1. Dry (non-exudative) AMD
    • 2.6.2. Wet (exudative) AMD
    • 2.6.3. Risk Factors For AMD
    • 2.6.4. Diagnosis of AMD
    • 2.6.5. Treatment of AMD
  • 2.7. Diabetic Retinopathy (DR)
    • 2.7.1. Diagnosis of Diabetic Retinopathy
    • 2.7.2. Risk factor of Diabetic Retinopathy
    • 2.7.3. Treatment of Diabetic Retinopathy
  • 2.8. Ocular Allergy and Allergic Conjunctivitis
    • 2.8.1. Diagnosis of Ocular Allergy
    • 2.8.2. Treatment of Ocular Allergy
  • 2.9. Ocular Inflammatory Disease
    • 2.9.1. Risk factors of Ocular Inflammatory Disease
    • 2.9.2. Treatment of Ocular Inflammatory Disease
  • 2.10. Eye Infections
    • 2.10.1. Treatment of Eye Infections
  • 2.11. Dry Eye Syndrome
    • 2.11.1. Treatment of Dry Eye Syndrome
  • 2.12. Phases of Clinical Trials
  • 2.13. Ophthalmic Drugs: Market Definition in This Report

3. The Global Ophthalmic Drugs Market, 2017-2027

  • 3.1. The Global Ophthalmic Drugs Market: Market Overview
  • 3.2. Categorisation of the Global Ophthalmic Drugs Market
  • 3.3. The Global Ophthalmic Drugs Market In 2016
  • 3.4. The Global Ophthalmic Drugs Market: Market Forecast 2017-2027
  • 3.5. Ophthalmic Drugs: Changing Market Shares by Sector 2017-2027

4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2016-2027

  • 4.1. Leading Products in the Retinal Disorder Drugs Market, 2016
  • 4.2. Retinal Disorders: Market Trends and Developments, 2016
    • 4.2.1. The Rise and Rise of Eylea
    • 4.2.2. The Debate Around Off-Label Avastin Use and The Role of Novartis And Roche
    • 4.2.3. How Likely Is Avastin's Expansion into Age-Related Macular Degeneration?
    • 4.2.4. Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
    • 4.2.5. Drug/Device Combination Products Entering the Market
    • 4.2.6. Does Regenerative Medicine Have a Successful Future in Ophthalmics?
  • 4.3. Retinal Disorder Drugs: Market Forecast 2017-2027
    • 4.3.1. Retinal Disorder Drugs: Changing Market Shares by Leading Drugs 2017-2027
  • 4.4. Leading Drugs for The Treatment of Retinal Disorders
  • 4.5. Eylea (aflibercept) - Regeneron/ Bayer/ Santen
    • 4.5.1. Recent Approvals for Eylea
    • 4.5.2. Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
    • 4.5.3. Eylea: Sales Forecast 2016-2027
    • 4.5.4. Possible Combination Therapies Involving Eylea
  • 4.6. Lucentis (ranibizumab) - Roche/ Novartis
    • 4.6.1. Lucentis: Sales Forecast 2016-2027
    • 4.6.2. Less Frequent Dosing Approved in US for Lucentis
    • 4.6.3. New Indications for Lucentis
    • 4.6.4. Possible Combination Therapy Involving Lucentis
  • 4.7. Avastin (bevacizumab) - Roche
    • 4.7.1. Avastin: Sales Forecast 2017-2027
    • 4.7.2. Compounding Pharmacies and Safety Risks
  • 4.8. Visudyne (verteporfin) - Valeant/ Novartis
    • 4.8.1. Visudyne: Sales Forecast 2016-2027
  • 4.9. Jetrea (ocriplasmin) - ThromboGenics/ Novartis
    • 4.9.1. Jetrea: Recent Sales Performance
    • 4.9.2. Clinical Study Plans for Jetrea
    • 4.9.3. Jetrea: Sales Forecast 2016-2027
    • 4.9.4. Possible Acquisition Move on ThromboGenics
    • 4.9.5. R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
  • 4.10. Other Retinal Disorder Drugs
    • 4.10.1. Iluvien (fluocinolone implant) - Alimera Sciences
    • 4.10.2. Ozurdex (dexamethasone implant) - Allergan
    • 4.10.3. Other Retinal Disorder Drugs: Sales Forecast 2016-2027

5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis and Forecast 2016-2027

  • 5.1. Leading Products in The Allergic, Inflammatory and Infective Drugs Market, 2016
  • 5.2. Allergic, Inflammatory and Infective Drugs: Market Trends and Developments, 2016
    • 5.2.1. The Growth Prospects for Allergic, Inflammatory and Infective Drugs
    • 5.2.2. Topical NSAIDs Launched: Prolensa and Ilevro
  • 5.3. Allergic, Inflammatory and Infective Drugs: Market Forecast 2016-2027
    • 5.3.1. Allergic, Inflammatory and Infective Drugs: Changing Market Shares by Leading Drugs 2017-2027
  • 5.4. Leading Drugs for The Treatment of Allergic, Inflammatory and Infective Ophthalmic Conditions
  • 5.5. Patanol And Pataday (olopatadine) - Alcon (Novartis)
    • 5.5.1. Pataday: Sales Forecast 2016-2027
    • 5.5.2. Impending Generic Competition for Patanol And Pataday
    • 5.5.3. Approval of Pazeo Solution
    • 5.5.4. Patanol: Sales Forecast 2016-2027
  • 5.6. Vigamox (moxifloxacin) - Alcon (Novartis)
    • 5.6.1. Intensifying Competition and Generics Drug Challenge to Vigamox
    • 5.6.2. Moxeza: A Next-Generation Form of Vigamox
    • 5.6.3. Vigamox: Sales Forecast 2016-2027
  • 5.7. TobraDex (tobramycin/dexamethasone) - Alcon (Novartis)
    • 5.7.1. The Development and Commercialisation of TobraDex ST
    • 5.7.2. TobraDex: Sales Forecast 2016-2027
  • 5.8. Cravit (levofloxacin) - Santen
    • 5.8.1. Cravit: Sales Forecast 2016-2027
  • 5.9. Acular (ketorolac) - Allergan (Actavis)
    • 5.9.1. Acular: Sales Forecast 2016-2027
  • 5.10. AzaSite (azithromycin) - Akorn
    • 5.10.1. AzaSite: Sales Forecast 2016-2027
  • 5.11. Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast 2016-2027

6. Glaucoma Drugs Market: Market Analysis and Forecast 2016-2027

  • 6.1. Glaucoma Drugs: Market Overview
    • 6.1.1. Leading Products in The Glaucoma Drugs Market, 2016
  • 6.2. Glaucoma Drugs: Market Trends and Developments, 2017
    • 6.2.1. Patent Expiration: A Major Restraint for Glaucoma Drugs
    • 6.2.2. Preservative-Free Formulation Trends
    • 6.2.3. Innovation in Treatments for Glaucoma
  • 6.3. Simbrinza: First Beta-Blocker-Free Combination
  • 6.4. Glaucoma Drugs: Market Forecast 2016-2027
    • 6.4.1. Glaucoma Drugs: Changing Market Shares by Leading Drugs 2016-2027
  • 6.5. Leading Drugs for The Treatment of Glaucoma
  • 6.6. Lumigan And Ganfort (bimatoprost) - Allergan (Actavis)
    • 6.6.1. Lumigan And Ganfort: Sales Forecast 2017-2027
  • 6.7. Xalatan And Xalacom (latanoprost) - Pfizer
    • 6.7.1. Xalatan/Xalacom: Sales Forecast 2017-2027
  • 6.8. Travatan/Travatan Z and DuoTrav (travoprost) - Novartis
    • 6.8.1. Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2027
  • 6.9. Alphagan/Alphagan P and Combigan (brimonidine) - Allergan
    • 6.9.1. Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2027
  • 6.10. Trusopt And Cosopt/Cosopt PF (dorzolamide) - Merck/ Santen
    • 6.10.1. Divestment Agreement with Santen And Akorn
    • 6.10.2. Trusopt: Sales Forecast 2017-2027
    • 6.10.3. Cosopt And Cosopt PF: Sales Forecast 2017-2027
  • 6.11. Azopt (brinzolamide) - Novartis
    • 6.11.1. Azopt: Sales Forecast 2017-2027
  • 6.12. Tapros (tafluprost) - Santen
    • 6.12.1. Tapros: Sales Forecast 2016-2027
  • 6.13. Zioptan (tafluprost) - Akorn
    • 6.13.1. Zioptan: Sales Forecast 2016-2027
  • 6.14. Other Glaucoma Drugs: Sales Forecast 2017-2027

7. Dry Eye Drugs Market: Market Analysis and Forecast 2016-2027

  • 7.1. Dry Eye Drugs: Market Overview
    • 7.1.1. Leading Products in The Dry Eye Drugs Market, 2016
  • 7.2. Dry Eye Drugs: Market Trends and Developments, 2016
    • 7.2.1. Restasis: Patent Elongations and Generic Challenges Creating Uncertainty
    • 7.2.2. Intensifying Research Focused on Dry Eye
    • 7.2.3. Improving Diagnostic Tools
  • 7.3. Dry Eye Drugs: Market Forecast 2017-2027
    • 7.3.1. Dry Eye Drugs: Changing Market Shares by Leading Drugs 2017-2027
  • 7.4. Leading Drugs for The Treatment of Dry Eye
  • 7.5. Restasis (ciclosporin) - Allergan (Actavis)
    • 7.5.1. Restasis - Generic launch in 2016?
  • 7.5.2. Restasis: Sales Forecast 2017-2027
  • 7.6. Refresh Brand Products - Allergan (Actavis)
    • 7.6.1. Refresh Brand Products: Sales Forecast 2017-2027
  • 7.7. Hyalein (hyaluronic acid) - Santen
    • 7.7.1. Hyalein: Sales Forecast 2017-2027
  • 7.8. Diquas (diaquafosol) - Santen
    • 7.8.1. Diquas: Sales Forecast 2017-2027
  • 7.9. Other Dry Eye Drugs: Sales Forecast 2017-2027
  • 7.10. Other Ophthalmic Drugs
    • 7.10.1. Hetlioz (tasimelteon) - Vanda Pharmaceuticals
    • 7.10.2. Hetlioz: Sales Forecast 2017-2027

8. Leading National Markets for Ophthalmic Drugs, 2017-2027

  • 8.1. The Ophthalmic Drugs Market by Region
    • 8.1.1. The Global Distribution of Ophthalmic Drugs In 2016
  • 8.2. Leading National Markets: Forecast 2017-2027
    • 8.2.1. Changing Market Shares by Region, 2017-2027
  • 8.3. Regional Ophthalmic Drugs Markets: Analysis and Forecasts, 2017-2027
  • 8.4. United States: The Largest Ophthalmic Drugs Market
    • 8.4.1. How Will the Rise of a Biosimilars Market Impact on US Ophthalmic Drugs?
    • 8.4.2. US Ophthalmic Drugs Market: Market Forecast 2017-2027
  • 8.5. EU5
    • 8.5.1. EU5 Ophthalmic Drugs Market: Market Forecast 2016-2027
    • 8.5.2. Germany
    • 8.5.3. France
    • 8.5.4. UK
    • 8.5.5. Italy
    • 8.5.6. Spain
  • 8.6. Japan
    • 8.6.1. The Cost of Treatment in Japan
    • 8.6.2. Japanese Pharmaceutical Industry Regulatory Reform
    • 8.6.3. Japanese Ophthalmic Drugs Market Forecast 2017-2027
  • 8.7. China
    • 8.7.1. Expansion of Healthcare Coverage and Reimbursement in China
    • 8.7.2. Price Controls and The Anhui Model
    • 8.7.3. Chinese Ophthalmic Drugs Market: Market Forecast 2016-2027
  • 8.8. Brazil
    • 8.8.1. How Will Brazil's Growing Healthcare Influence Ophthalmic Drugs
    • 8.8.2. Brazilian Ophthalmic Drugs Market: Market Forecast 2017-2027
  • 8.9. Russia
    • 8.9.1. How Will Russia's Economic Status Affect Its Pharma Industry?
    • 8.9.2. Russian Ophthalmic Drugs Market: Market Forecast 2016-2027
  • 8.10. India
    • 8.10.1. The Impact of The Drug Prices Control Order on Indian Pharma
    • 8.10.2. India's Expansion of Healthcare Provision
    • 8.10.3. Indian Ophthalmic Drugs Market: Market Forecast 2017-2027
  • 8.11. Rest of the World
    • 8.11.1. Rest of the World Ophthalmic Drugs Market: Market Forecast 2017-2027

9. Leading Companies in the Ophthalmic Drugs Market, 2017-2027

  • 9.1. Ophthalmic Drugs - A Changing Market Landscape
  • 9.2. Leading Companies in The Ophthalmic Drugs Market, 2016
    • 9.2.1. Ophthalmic Drugs Market: Leading Companies Forecast 2017-2027
    • 9.2.2. Ophthalmic Drugs: Changing Market Shares by Leading Companies 2017-2027
  • 9.3. Novartis (Alcon)
    • 9.3.1. Novartis: Ophthalmic Drugs Portfolio, 2016
    • 9.3.2. Novartis: Sales Forecast 2016-2027
    • 9.3.3. Novartis: Ophthalmic Drugs Development Pipeline, 2016
    • 9.3.4. Novartis: Recent Developments
  • 9.4. Regeneron
    • 9.4.1. Regeneron: Ophthalmic Drugs Portfolio, 2016
    • 9.4.2. Regeneron: Recent Developments
    • 9.4.3. Regeneron: Sales Forecast 2017-2027
    • 9.4.4. Regeneron: Ophthalmic Drugs Development Pipeline, 2016
  • 9.5. Allergan (Actavis)
    • 9.5.1. Allergan: Ophthalmic Drugs Portfolio
    • 9.5.2. Allergan: Recent Developments
    • 9.5.3. New acquisitions for healthcare development
    • 9.5.4. Allergan: Sales Forecast 2017-2027
    • 9.5.5. Allergan: Ophthalmic Drugs Development Pipeline, 2016
  • 9.6. Roche
    • 9.6.1. Roche: Ophthalmic Drugs Portfolio, 2016
    • 9.6.2. Roche: Sales Forecast 2017-2027
    • 9.6.3. Roche: Ophthalmic Drugs Development Pipeline, 2016
  • 9.7. Valeant
    • 9.7.1. Valeant: Ophthalmic Drugs Portfolio, 2016
    • 9.7.2. Valeant: Recent Developments
    • 9.7.3. Valeant: Sales Forecast 2017-2027
    • 9.7.4. Valeant: Ophthalmic Drugs Development Pipeline, 2016
    • 9.7.5. Valeant: Difficult End to 2015 as well as 2016 Leads to Uncertainty About Company Future
  • 9.8. Santen
    • 9.8.1. Santen: Ophthalmic Drugs Portfolio, 2016
    • 9.8.2. Santen: Recent Developments
    • 9.8.3. Santen: Sales Forecast 2017-2027
    • 9.8.4. Santen: Ophthalmic Drugs Development Pipeline, 2016
  • 9.9. Bayer
    • 9.9.1. Bayer: Ophthalmic Drugs Portfolio
    • 9.9.2. Bayer: Sales Forecast 2017-2027
  • 9.10. Pfizer
    • 9.10.1. Pfizer: Ophthalmic Drugs Portfolio, 2017
    • 9.10.2. Pfizer: Recent Developments
    • 9.10.3. Pfizer: Sales Forecast 2017-2027
    • 9.10.4. Pfizer: Ophthalmic Drugs Development Pipeline, 2017
  • 9.11. Senju
    • 9.11.1. Senju: Ophthalmic Drugs Portfolio
    • 9.11.2. Senju: Sales Forecast 2017-2027
    • 9.11.3. Senju: Ophthalmic Drugs Development Pipeline, 2016

10. Ophthalmic Drugs: Research and Development Pipeline, 2017-2027

  • 10.1. The Ophthalmic Drugs Pipeline: Intensive Development Efforts in Retinal Disorders
  • 10.2. Drugs for Retinal Disorders: Development Pipeline, 2016
    • 10.2.1. Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
  • 10.3. Retinal Disorders: Filed or Recently Launched
    • 10.3.1. CompaqSipp (conbercept) - Chengdu Kanghong Pharmaceutical
    • 10.3.2. Lipidil (fenofibrate) - Abbott
    • 10.3.3. Iluvien (fluocinolone) - AlimeraSciences
  • 10.4. Drugs in Phase 3 Development For Retinal Disorders
    • 10.4.1. AGN150998 And MP0260 (Anti-VEGFDARPins) - Allergan
    • 10.4.2. Fovista and Zimura - Ophthotech Corporation
    • 10.4.3. Lampalizumab (anti-FactorD Fab) - Roche
    • 10.4.4. MC-1101 (hydralazine) - Macu CLEAR
    • 10.4.5. Squalamine (anti-angiogenic drug) - OHRPharmaceutical
    • 10.4.6. Tandospirone (serotonin 1A agonist) - Alcon (Novartis)
    • 10.4.7. UF-021 (unoprostone) - R-TechUeno
  • 10.5. Drugs in Phase 2 Development for Retinal Disorders
    • 10.5.1. AKB-9778 (Tie2 activator) - AerpioTherapeutics
    • 10.5.2. Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju
    • 10.5.3. AGN208397 (beclomethasone) - Allergan
    • 10.5.4. CPC 551 - ColbyPharmaceutical
    • 10.5.5. ESBA1008 (anti-VEGF mAb) - Alcon (Novartis)
    • 10.5.6. iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics
    • 10.5.7. LFG316 (anti-C5 mAb) - Novartis
    • 10.5.8. Intravitreal brimonidine implant - Allergan
    • 10.5.9. Optina (danazol) - AmpioPharmaceuticals
    • 10.5.10. PF-655 (synthetic siRNA) - Quark/Pfizer
    • 10.5.11. Premiplex (SHP-607) - Shire
    • 10.5.12. Renexus (ciliary neurotrophic factor) - Neurotech
    • 10.5.13. Zybrestat (fosbretabulin) - Oxigene/SymphonyVIDA
  • 10.6. DrugsInPhase 1 and Pre-clinical Developmentfor RetinalDisorders
    • 10.6.1. BDM-E - BioDiem
    • 10.6.2. NADPHOxidaseInhibitors - AlimeraSciences
    • 10.6.3. PAN-90806 (topical VEGF inhibitor) - PanOptica
    • 10.6.4. PlasmaKallikreinInhibitors (KVD001) - KalVista
    • 10.6.5. QLT091001 (synthetic retinoid) - QLT
  • 10.7. Drugs in Phase 3 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
    • 10.7.1. EGP-437 (dexamethasone) - EyeGatePharmaceuticals
    • 10.7.2. IBI-10090 and IBI-20089 - IconBioscience
    • 10.7.3. KPI-121 (loteprednol etabonate) - Kala
  • 10.8. Drugs in Phase 2 Development for Allergic, Inflammatory And Infective Ophthalmic Conditions
    • 10.8.1. CF101 (adenosine A3 receptor agonist) - Can-FiteBioPharma and OphthaliX
    • 10.8.2. FST-100 (povidone-iodine/dexamethasone) - Shire
    • 10.8.3. NVC-422 (auriclosene) - NovaBay
    • 10.8.4. Sarilumab - Regeneron
  • 10.9. Drugs in Phase 1 And Pre-clinical Development For Allergic, Inflammatory and Infective Ophthalmic Conditions
    • 10.9.1. Finafloxacin - MerLionPharmaceuticals/Novartis
  • 10.10. Drugs for Glaucoma: Development Pipeline, 2016
  • 10.11. Drugs in Phase 2&3 Development for Glaucoma
    • 10.11.1. Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
    • 10.11.2. AMA0076 (ROCK inhibitor) - Amakem
    • 10.11.3. Rhopressa (AR-13324; ROCK and NET inhibitor) AndRoclatan (PG324; ROCK inhibitor) - Aerie Pharmaceuticals
  • 10.12. Drugs in Phase 1 And Pre-clinical Development For Glaucoma
  • 10.13. Drugs in Phase 3 Development for Dry Eye
    • 10.13.1. EBI-005 (IL-1R antagonist) - Eleven Biotherapeutics
    • 10.13.2. Lifitegrast (integrin antagonist) - Shire
    • 10.13.3. Tavilermide (formerly MIM-D3tyrosine kinase receptor antagonist) - Allergan
    • 10.13.4. SI-614 (modified hyaluronate) - Seikagaku
  • 10.14. Drugs in Phase 2 Development for Dry Eye
    • 10.14.1. ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
    • 10.14.2. Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
  • 10.15. Other Drugs in the Development Pipeline for Ophthalmic Conditions
    • 10.15.1. Brimonidine For Eye Whitening - Valeant
    • 10.15.2. GS-101 (aganirsen) - GeneSignal
    • 10.15.3. Omidria (phenylephrine/ketorolac) - Omeros

11. Qualitative Analysis of the Ophthalmic Drugs Market, 2017-2027

  • 11.1. Market Factors Influencing Ophthalmic Drugs
  • 11.2. SWOT Analysis of the Global Ophthalmic Drugs Market, 2017-2027
  • 11.3. Strengths
    • 11.3.1. A Healthy R&D Pipeline
    • 11.3.2. Advances in Drug Delivery Technologies
    • 11.3.3. Support for Reimbursement and Payment Approvals
    • 11.3.4. Gene Therapy and RNAi Technology
    • 11.3.5. New Ophthalmic Therapeutic Applications for Drugs
    • 11.3.6. Development of Neuroprotective Anti-Glaucoma Medications
    • 11.3.7. Biomarkers as Tools for Better Diagnosis and Treatment
  • 11.4. Weaknesses
    • 11.4.1. Low Levels of Patient Adherence to Treatment
    • 11.4.2. High Treatment Burden on Patients And Healthcare Providers
    • 11.4.3. Under-Diagnosis and Under-Treatment
  • 11.5. Opportunities
    • 11.5.1. Sustained-Release Ocular Implants
    • 11.5.2. The Impact of a Rapidly Ageing Global Population
    • 11.5.3. Increasing Prevalence of Diabetes and Ocular Disease
    • 11.5.4. Glaucoma and Retinal Disorders Set for Most-Marked Increases in Prevalence
    • 11.5.5. Unmet Clinical Need in Many Disease Areas
    • 11.5.6. Economic Growth in Emerging Market Provide Opportunity for Expansion
  • 11.6. Threats
    • 11.6.1. Intensifying Price Regulation in The Market
    • 11.6.2. Generic Competition - Likely to Cause Erosion of Sales for Market Leading Brands
    • 11.6.3. Rising Cost Of R&D
    • 11.6.4. Biosimilars - A Bigger Threat than Generics?
  • 11.7. Porter's Five Force Analysis of The Global Ophthalmic Drugs Market, 2017-2027
    • 11.7.1. Threat of New Entrants
    • 11.7.2. Rivalry Among Competitors
    • 11.7.3. Power of Suppliers
    • 11.7.4. Threat of Substitutes
    • 11.7.5. Power of Buyers

12. Conclusions

  • 12.1. Overview of Current Market Conditions and Market Forecast, 2016-2027
  • 12.2. Leading Sectors in Ophthalmic Drugs In 2016
  • 12.3. Leading Regions in The Ophthalmic Drugs Market In 2016
  • 12.4. Leading Companies in The Ophthalmic Drugs Market, 2016
  • 12.5. What Does the Future Hold for Ophthalmic Drugs?

13. Glossary

  • Associated Report
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 1.1: Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Country, 2016-2027 (Redacted Data)
  • Table 2.1: ICD 10 Classification of Visual Impairment, 2010
  • Table 2.2: Main Classes of the Glaucoma Drugs, 2016
  • Table 2.3: Drug Treatments for Age-Related Macular Degeneration, 2017
  • Table 2.4: Drug Treatments for Ocular Allergy, 2016
  • Table 2.5: Drug Treatments for Ocular Inflammatory Disease, 2017
  • Table 2.6: Drug Treatments for Eye Infections, 2017
  • Table 2.7: Clinical Trial Phases, 2016
  • Table 3.1: The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2016
  • Table 3.2: The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2016-2027
  • Table 3.3: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2016-2021, 2021-2027, 2017-2027
  • Table 3.4: The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2016, 2021, 2027
  • Table 4.1: Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2016
  • Table 4.2: Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 4.3: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 4.4: Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR (%) and CAGR(%), 2016-2027
  • Table 4.5: Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 4.6: Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 4.7: Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 4.8: Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 4.9: Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.1: Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2016
  • Table 5.2: Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 5.3: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 5.4: Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.5: Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.6: Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.7: TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.8: Cravit: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.9: Acular: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.10: AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 5.11: Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.1: Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2016
  • Table 6.2: Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 6.3: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 6.4: Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.5: Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.6: Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.7: Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.8: Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.9: Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.10: Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.11: Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.12: Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 6.13: Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 7.1: Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2016
  • Table 7.2: Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2016-2027
  • Table 7.3: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2016, 2021, 2027
  • Table 7.4: Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 7.5: Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 7.6: Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 7.7: Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 7.8: Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2016-2027
  • Table 7.9: Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.1: The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2016
  • Table 8.2: Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2016-2027
  • Table 8.3: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2016-2021, 2021-2027, and 2017-2027
  • Table 8.4: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2016, 2021, and 2027
  • Table 8.5: The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.6: US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.7: The EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2016-2027
  • Table 8.8: The EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2016
  • Table 8.9: The EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.10: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2016, 2021, 2027
  • Table 8.11: The German Ophthalmic Drugs Market F orecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2027
  • Table 8.12: The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 8.13: The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.14: The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 8.15: The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.16: The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.17: The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.18: The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.19: The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.20: The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.21: The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2027
  • Table 8.22: The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.23: The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.24: The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.25: The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.26: The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.27: The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.28: The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 8.29: The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.30: The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 8.31: The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2016-2027
  • Table 8.32: The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.1: Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2016
  • Table 9.2: Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2016-2027
  • Table 9.3: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2016, 2021, 2027
  • Table 9.4: Novartis: Company Overview, 2016
  • Table 9.5: Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2017-2027
  • Table 9.6: Regeneron: Company Overview, 2016
  • Table 9.7: Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.8: Allergan: Company Overview, 2016
  • Table 9.9: Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.10: Roche: Company Overview, 2016
  • Table 9.11: Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.12: Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.13: Valeant: Company Overview, 2016
  • Table 9.14: Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.15: Santen: Company Overview, 2016
  • Table 9.16: Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.17: Bayer: Company Overview, 2016
  • Table 9.18: Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.19: Pfizer: Company Overview, 2016
  • Table 9.20: Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 9.21: Senju: Company Overview, 2016
  • Table 9.22: Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2016-2027
  • Table 10.1: RetinalDisordersDrugsPipeline: Phase 3 Drugs, 2016
  • Table 10.2: RetinalDisordersDrugsPipeline: Phase 2 Drugs, 2016
  • Table 10.2: RetinalDisordersDrugsPipeline: Phase 2 Drugs, 2016 (continued)
  • Table 10.3: RetinalDisordersDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016
  • Table 10.4: Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 3 Drugs, 2016
  • Table 10.5: Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 2Drugs, 2016
  • Table 10.6: Allergic, Inflammatory and InfectiveDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016
  • Table 10.7: GlaucomaDrugsPipeline: Phase 2&3 Drugs, 2016
  • Table 10.8: GlaucomaDrugsPipeline: Phase 1 and Pre-clinical Drugs, 2016
  • Table 10.9: DryEyeDrugsPipeline: Phase 3 Drugs, 2016
  • Table 10.10: DryEyeDrugsPipeline: Phase 2 Drugs, 2016
  • Table 10.11: OtherPipelineProducts for OphthalmicConditions, 2016
  • Table 11.1: SWOT Analysis of the Global Ophthalmic Drugs Market, 2017-2027
  • Table 11.2: World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2016-2027
  • Table 11.3: Global Prevalence Forecast for Ophthalmic Diseases
  • Table 12.1: Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2016, 2021, 2027
  • Table 12.2: The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2016, 2021, 2027

List of Figures

  • Figure 1.1: Global Ophthalmic Drugs Market: Market Sectors, 2017
  • Figure 2.1: Structure of The Human Eye
  • Figure 2.2: Estimated Global Prevalence of Visual Impairment (millions of people), 2014
  • Figure 2.3: Global Causes of Visual Impairment (% of cases), 2012
  • Figure 2.4: Classification of Glaucoma, 2016
  • Figure 3.1: The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2016
  • Figure 3.2: The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 3.3: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2016-2021
  • Figure 3.4: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2021-2027
  • Figure 3.5: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2017-2027
  • Figure 3.6: The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2016
  • Figure 3.7: The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2021
  • Figure 3.8: The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2027
  • Figure 4.1: Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m), 2016
  • Figure 4.2: Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 4.3: Retinal Disorder Drugs Market: Revenue Forecast ($m, AGR%) by Leading Drugs, 2016-2027
  • Figure 4.4: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 4.5: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 4.6: The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 4.7: Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2016-2027
  • Figure 4.8: Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2016-2027
  • Figure 4.9: Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2016-2027
  • Figure 4.10: Visudyne: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 4.11: Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2016-2027
  • Figure 4.12: Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.1: Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2016
  • Figure 5.2: Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 5.3: Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2016-2027
  • Figure 5.4: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 5.5: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 5.6: The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 5.7: Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.8: Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.9: Vigamox: Novartis Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.10: TobraDex: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.11: Cravit: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.12: Acular: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.13: AzaSite: Akorn Sales Forecast ($m, AGR%), 2016-2027
  • Figure 5.14: Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.1: Leading Glaucoma Drugs: Revenue ($m), 2016
  • Figure 6.2: Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 6.3: Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2016-2027
  • Figure 6.4: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 6.5: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 6.6: The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 6.7: Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.8: Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.9: Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.10: Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.11: Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.12: Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.13: Azopt: Novartis Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.14: Tapros: Santen Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.15: Zioptan: Akorn Sales Forecast ($m, AGR%), 2016-2027
  • Figure 6.16: Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2016-2027
  • Figure 7.1: Leading Dry Eye Drugs: Revenue ($m), 2016
  • Figure 7.2: Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 7.3: Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2016-2027
  • Figure 7.4: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2016
  • Figure 7.5: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2021
  • Figure 7.6: The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2027
  • Figure 7.7: Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2016-2027
  • Figure 7.8: Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2016-2027
  • Figure 7.9: Hyalein: Santen Sales Forecast ($m, AGR%), 2016-2027
  • Figure 7.10: Diquas: Santen Sales Forecast ($m, AGR%), 2016-2027
  • Figure 7.11: Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2016-2027
  • Figure 7.12: Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2016-2027
  • Figure 8.1: The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2016
  • Figure 8.2: US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2016-2027
  • Figure 8.3: Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2016-2027
  • Figure 8.4: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2016-2021
  • Figure 8.5: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2021-2027
  • Figure 8.6: The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2017-2027
  • Figure 8.7: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2016
  • Figure 8.8: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2021
  • Figure 8.9: The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2027
  • Figure 8.10: US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.11: The EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2016
  • Figure 8.12: Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2016-2027
  • Figure 8.13: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2016
  • Figure 8.14: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2021
  • Figure 8.15: The EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2027
  • Figure 8.16: The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.17: The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.18: The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.19: The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
  • Figure 8.20: The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
  • Figure 8.21: The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
  • Figure 8.22: The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
  • Figure 8.23: The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.24: The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2017-2027
  • Figure 8.25: The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 8.26: The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2016-2027
  • Figure 9.1: Leading Ophthalmic Drug Companies: Revenue ($m), 2016
  • Figure 9.2: Ophthalmic Drugs Market: Market Forecast ($m) by Leading Companies, 2016-2027
  • Figure 9.3: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2016
  • Figure 9.4: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2021
  • Figure 9.5: The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2027
  • Figure 9.6: Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.7: Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.8: Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.9: Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.10: Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.11: Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.12: Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.13: Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.14: Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 9.15: Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2016-2027
  • Figure 11.1: World 65+ Population Forecast: Size (m), AGR (%), 2016-2027
  • Figure 11.2: Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
  • Figure 11.3: Porter's Five Force Analysis of the Ophthalmic Drugs Market, 2016
  • Figure 12.1: Global Ophthalmic Drugs: Market Forecast ($m), 2016, 2021, 2027
  • Figure 12.2: The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2016-2027

Companies Mentioned in the Report:

  • Acucela
  • Actavis
  • Advanced Cell Technologies
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Alcon
  • Alembic
  • Algeta
  • Alimera Sciences
  • Allegro
  • Allergan
  • Akorn
  • Amakem
  • Amgen
  • Ampio Pharmaceuticals
  • Apotex
  • Asahi Glass
  • AstraZeneca
  • Aurobindo Pharma Ltd
  • Aventis
  • Barr Laboratories
  • Bausch & Lomb
  • Biocad
  • BioDiem
  • Biovail Corporation
  • BioXpress Therapeutics
  • Bristol-Myers Squibb
  • Can-Fite BioPharma
  • Cipla
  • Chengdu Kanghong Pharmaceutical
  • Chiesi Farmaceutici S.p.A
  • Chiron Corporation
  • Chugai Pharmaceutical
  • CIBA VISION
  • Colby Pharmaceuticals
  • Daiichi Sankyo
  • Eleven Biotherapeutics
  • Eli Lilly
  • ESBATech
  • EyeCyte
  • EyeGate
  • Eyetech Pharmaceuticals
  • ForeSight Biotherapeutics
  • ForSight VISION4
  • Fougera Pharmaceuticals
  • Gene Signal
  • Genentech
  • GlaxoSmithKline
  • Hospira
  • iCo Therapeutics
  • Icon Bioscience
  • InSite Vision
  • Inspire Pharmaceuticals
  • Instituto Terapeutico Delta Ltda
  • Jenapharm
  • Johnson & Johnson
  • Kala Pharmaceuticals
  • KalVista
  • Kestrel Ophthalmics
  • Kyorin Pharmaceutical
  • Kyowa Hakko Kirin
  • LEO Pharma
  • Lpath
  • MacuCLEAR
  • MacuSight
  • MAP Pharmaceuticals
  • MEAgate International FZLLC
  • Meda
  • Merck & Co. (Merck)
  • MerLion
  • Molecular Partners
  • MSD K.K.
  • Neurim Pharmaceuticals
  • Neurotech
  • NovaBay
  • Novagali
  • Novartis
  • Novel Labs Inc
  • OHR Pharmaceutical
  • Omeros
  • OphthaliX
  • Ophthotech
  • PanOptica
  • Patheon Pharmaceuticals
  • Par Pharmaceutical
  • Pfizer
  • Pharmacia
  • PreCision Dermatology
  • Procter & Gamble
  • pSivida
  • QLT
  • Quark Pharmaceuticals
  • Regeneron
  • Reckitt Benckiser
  • Roche
  • Roche Consumer Health
  • R-Tech Ueno
  • RXi Pharmaceuticals
  • Salix
  • Sanofi
  • Sandoz
  • Santaris Pharma
  • Santen
  • Schering AG
  • Seikagaku
  • Senju
  • Servier
  • Shire
  • SkinMedica
  • Sobi
  • Stelgerwald
  • Spark Therapeutics
  • Takeda
  • ThromboGenics
  • Upjohn
  • UV North America
  • Valeant
  • Vanda Pharmaceuticals
  • Ventana Medical Systems
  • Warburg Pincus LLC
  • Watson
  • Wockhardt
  • Wyeth Pharmaceuticals
  • Zach System Spa

Organizations Mentioned in the Report:

  • A*STAR Institute for Infocomm Research (Singapore)
  • American Academy of Ophthalmology (AAO)
  • American Diabetes Association
  • American Society of Retina Specialists (ASRS)
  • Association for Research in Vision and Ophthalmology (ARVO)
  • Australian Therapeutic Goods Administration
  • Emory University
  • European Medicines Agency (EMA)
  • Health Canada
  • Italian National Health Service
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • Japan Patent Office
  • Johns Hopkins University (Baltimore, US)
  • National Institute of Clinical Excellence (NICE)
  • National Institute of Health (NIH)
  • Ophthalmic Drugs Advisory Committee - Division of the FDA
  • Portsmouth Primary Care Trust
  • Tokyo University of Science
  • UK National Health Service (NHS)
  • United Nations Department of Economic and Social Affairs, Population Division
  • University of Modena and Reggio Emilia
  • US Food and Drug Agency (FDA)
  • US National Eye Institute (NEI)
  • US Preventive Services Task Force
  • World Health Organization (WHO)
Back to Top